Immunomodulatory treatment for dermatomyositis

Current Allergy and Asthma Reports

Volumn 8, Issue 4, 2008, Pages 348-353

  Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIESTROGEN; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CHLORAMBUCIL; CORTICOSTEROID; CREATINE; CYCLOSPORIN; DILTIAZEM; EFALIZUMAB; ETANERCEPT; FLUDARABINE; FOLIC ACID; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; PREDNISONE; PROBENECID; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CALCINOSIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED MYOPATHY; DERMATOMYOSITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ELECTROMYOGRAPHY; GASTROINTESTINAL TOXICITY; HUMAN; MULTICENTER STUDY; MUSCLE BIOPSY; MUSCLE CONTRACTURE; NAUSEA; PHOTOSENSITIVITY; POLYMYOSITIS; PROGNOSIS; PYURIA; REVIEW; SKIN BIOPSY; SKIN DISEASE; STOMATITIS; SUNLIGHT PROTECTION; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; METABOLISM; SKELETAL MUSCLE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; DERMATOMYOSITIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SKELETAL; POLYMYOSITIS;

EID: 50349096099     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0055-1     Document Type: Review

References (56)

1. Callen JP, Wortmann RL: Dermatomyositis. Clin Dermatol 2006, 24:363-373.
2. Callen JP: Dermatomyositis. Lancet 2000, 355:53-57.
3. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
4. Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407.
5. Gerami P, Schope JM, McDonald L, et al.: A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006, 54:597-613.
6. Pachman LM, Abbott K, Sinacore JM, et al.: Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006, 148:247-253.
7. Huber AM, Dugan EM, Lachenbruch PA, et al.: Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis Rheum 2008, 59:214-221.
8. Carroll CL, Lang W, Snively B, et al.: Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008, 158:345-350.
9. Gaines E, Werth VP: Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res 2008, 300:3-9.
10. Isenberg DA, Allen E, Farrell V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49-54.
11. Cordiero AC, Isenberg DA: Treatment of inflammatory myopathies. Postgrad Med J 2006, 82:417-424.
12. Fiorentino DF, Callen JP: Dermatomyositis. In Evidence Based Dermatology. Edited by Williams H, Bigby M, Diepgen T, et al. London: BMJ Press; 2008.
13. Winkelmann RK, Mulder DW, Lambert EH, et al.: Course of dermatomyositis-polymyositis: Comparison of untreated and cortisone-treated patients. Mayo Clin Proc 1968, 43:545-556.
14. Klein-Gitelman MS, Waters T, Pachman LM: The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000, 13:360-368.
15. Bohan A, Peter JB, Bowman RL, Pearson CM: Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977, 56:255-286.
16. Nzeusseu A, Brion F, Lefèbvre C, et al.: Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol 1999, 17:441-446.
17. Dawkins MA,AJorizzo JL, Walker FO, et al.: Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol, 1998, 38:397-404.
18. Bunch TW, Worthington JS, Combs JJ, et al.: Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980, 92:365-369.
19. Miller J, Walsh Y, Saminaden S, et al.: Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurological Sci 2002, 199(Suppl 1):S53.
20. Ramanan, AV, Campbell-Webster N, Ota S, et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52:3570-3578.
21. Villalba L, Adams EM, Sherman JB, et al.: Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41:392-399.
22. Kamel OWR van de Rijn M, Weiss LM, et al.: Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993, 328:1317-1321.
23. Waldman MA, Callen JP: Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 2004, 51(2 Suppl):S124-S130.
24. Bunch TW: Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981, 24:45-48.
25. Gelber AC, Nousari HC, Wigley FM: Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases. J Rheumatol 2000, 27:1542-1545.
26. Tausche AK, Meurer M: Mycophenolate mofetil for dermatomyositis. Dermatology 2001, 202:341-343.
27. Majithia V, Harisdangkul V: MAcophenolate mofetil (Cell-Cept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386-389.
28. Edge JC, Oultand JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
29. Rowin J, Amato AA, Deisher N, et al.: Mycophenolate mofetil in dermatomyositis: Is it safe? Neurology 2006, 66:1245-1247.
30. Vencovsky J, Jarosová K, Machácek S, et al.: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95-102.
31. Wilkes MR, Sereika SM, Fertig N, et al.: Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005, 52:2439-2446.
32. Sinoway PA, Callen JP: Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993, 36:319-324.
33. Adams EM,UPucino F, Yarboro C, et al.: A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 1999, 26:352-360.
34. Riley P, Maillard SM, Wedderburn LR, et al.: Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004, 43:491-496.
35. Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
36. Gottfried I., Seeber A, Anegg B, et al.: High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000, 10:29-35.
37. Levine TD: Rituximab in the treatment of Aermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607.
38. Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.
39. Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767.
40. Cooper MA, Willingham DL, Brown DE, et al.: Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. Arthritis Rheum 2007, 56:3107-3111.
41. Dinh HV, McCormack C, Hall S, Prince HM: Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases. J Am Acad Dermatol 2007, 56:148-153.
42. Efthimiou P, Schwartzman S, Kagen LJ: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: A retrospective study of eight patients. Ann Rheum Dis 2006, 65:1233-1236.
43. Dold S, Justiniano ME, Marquez J, Espinoza LR: Treatment of early and refractory dermatomyositis with infliximab: A report of two cases. Clin Rheumatol 2007, 26:1186-1188.
44. Iannone F, Scioscia C, Falappone PC, et al.: Use of etanercept in the treatment of dermatomyositis: A case series. J Rheumatol 2006, 33:1802-1804.
45. Hengstman GJ, De Bleecker JL, Feist E, et al.: Open-label trial of anti-TNF-alpha in dermato-and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59:159-163.
46. Quain RD, Werth VP: Management of cCtaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol 2006, 7:341-351.
47. Hollar CB, Jorizzo JL: Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: A pilot study. J Dermatolog Treat 2004, 15:35-39.
48. Woo TY, Callen JP, Voorhees JJ, et al.: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984, 10:592-600.
49. Ang GC, Werth VP: Combination antimalarials in the treatment of cutaneous dermatomyositis: A retrospective study. Arch Dermatol 2005, 141:855-859.
50. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD: Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995, 32(5 Pt 1):754-757.
51. Kasteler JS, Callen JP: Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 1997, 36:67-71.
52. Boswell JS, Costner M: Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008, 58:403-406.
53. Huber A, Gaffal E, Bieber T, et al.: Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol 2006, 86:254-255.
54. Sereda D, Werth VP: Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006, 142:70-72.
55. Pelle MT, Callen JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002, 138:1231-1233; discussion 1233.
56. Chung YL, Alexanderson H, Pipitone N, et al.: Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 57:694-702.